Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Doxil doxorubicin: Phase I/II data

In a Phase I/II trial in 36 evaluable patients, Doxil plus Rituxan rituximab led

Read the full 146 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE